September 14, 2018

September 14, 2018

Jennifer Greenman, 2018 CIO of the Year honoree

Tampa Bay Business Journal – Sept. 14

Jennifer Greenman joined Moffitt Cancer Center as the vice president of information technology and chief information officer in 2013. She’s had many accomplishments, both professionally and within the realm of community service.

 

Dr. Pinilla-Ibarz on the FDA Approval of Moxetumomab Pasudotox in Hairy Cell Leukemia

OncLive – Sept. 13

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

 

Daily aspirin may reduce ovarian cancer risk, extend survival

Healio – Sept. 13

Shelley S. Tworoger, PhD, associate center director for population science at Moffitt Cancer Center, and colleagues conducted the studies to help increase understanding of the potential role of inflammation in ovarian cancer development and progression.

 

Novel Agents Lead Charge Against Adult ALL

OncLive – Sept. 13

In a presentation during the 2018 OncLive® State of the Science Summit™ on Hematologic Malignancies, Julio C. Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discussed prognostic indicators and systemic treatment updates for patients with ALL.

 

With CRISPR, Scientists Engineered Nearly 4,000 Mutations of a Breast-Cancer Gene

The Atlantic – Sept. 12

In contrast, says Couch, who was not involved in the study, his frequent research collaborator Alvaro Monteiro at Moffitt Cancer Center has been analyzing mutations in BRCA1 one by one in cells growing in a lab. Over 15 years, he’s looked at 300 to 350 variants.

 

Shain Shares Strategies in Newly Diagnosed Myeloma

OncLive – Sept. 12

In an interview during the 2018 OncLive® State of the Science SummitTM on Hematologic Malignancies, Shain, an assistant member at Moffitt Cancer Center, discussed the evolution of treatment for patients with newly diagnosed multiple myeloma and how physicians are leveraging data with CAR T-cell therapy and minimal residual disease (MRD) negativity to improve outcomes.

 

Dr. Shain Discusses the Role of Stem Cell Transplant in Myeloma

OncLive – Sept. 12

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.

 

Dr. Pinilla-Ibarz on the Impact of Venetoclax in CLL

OncLive – Sept. 12

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the impact of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

 

Dr. Locke on Bridging Chemotherapy in Patients With Non-Hodgkin Lymphoma

OncLive – Sept. 12

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

 

CAR T Cells Continue to Be Leveraged in Lymphoma

OncLive – Sept. 12

“It's important that community oncologists realize that early referral for CAR T likely drives outcomes,” said Locke, a medical oncologist at Moffitt Cancer Center. 

 

Scientists Found a Intention to Engineer Virtually 4000 Mutations of a Breast-Cancer Gene

Newsline.com – Sept. 12

In distinction, says Couch, who was once not involved by the glance, his frequent learn collaborator Alvaro Monteiro at Moffitt Cancer Center has been analyzing mutations in BRCA1 one by one in cells rising in a lab. 

 

Meet Jennifer Greenman, a 2018 CIO of the Year honoree

Tampa Bay Business Journal – Sept. 11

Jennifer Greenman, vice president and chief information officer, H. Lee Moffitt Cancer Center & Research Institute

What was your first computer? “My family had an IBM PS/2 when I was a child. Interestingly, we had the Prodigy online service installed but lost interest as no one else we knew was “online” at that time in the 1980s.”

 

7 Ovarian Cancer Signs That Are Incredibly Easy To Miss

Women’s Health  Magazine – Sept. 11

This is generally a sign that ovarian cancer has spread, says Mitchel Hoffman, M.D., a gynecologic oncologist at Moffitt Cancer Center. "When we operate in ovarian cancer patients, the majority have metastasis," he says (meaning, it's spread to other areas).

 

Hollywood: A growing hub for healthcare innovation

South Florida Business Journal – Sept. 11

In addition, Memorial has partnered with Moffitt Cancer Center in Tampa to establish a Malignant Hematology & Cellular Therapy program, providing advanced bone and marrow cellular transplant care to leukemia and lymphoma patients. 

 

There Is No One-Size-Fits-All Approach to Treating MCL, Expert Says

Targeted Oncology – Sept. 11

In an interview with Targeted Oncology, Shah discussed the challenge of treating this highly heterogeneous disease, how to choose the optimal treatment regimen, and the ongoing role of BTK inhibitors.

 

Dr. Shah Compares Toxicity Profiles of Ibrutinib and Acalabrutinib

OncLive – Sept. 11

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib (Imbruvica) and acalabrutinib (Calquence).

 

Morphogenesis, Inc and the Cell and Gene Therapy Group at Karolinska Institutet Announce Collaboration to Develop Targeted Immunotherapies for the Treatment of Cancer

BioFlorida.com – Sept. 11

And in Tampa, FL, the Moffitt Cancer Center tested the company’s gene therapy in pre-clinical studies in preparation for a human melanoma clinical trial commencing this month.

 

Dr. Locke on CAR T-Cell Therapy in NHL

OncLive – Sept. 10

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

 

Sarcoma-Associated Gene Fusions a Result of ‘Genome Chaos’

Cancer Network – Sept. 10

Damon Reed, MD, program leader, Adolescent Young Adult Program at Moffitt Cancer Center in Tampa, Florida believes the study is exciting.

 

Which Is Best Neoadjuvant Chemo in Bladder Cancer?

Medscape – Sept. 10

The study, led by Scott M. Gilbert, MD, MS, from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, was published online August 30 in JAMA Oncology.

 

Olivia Newton-John diagnosed with cancer for 3rd time

WFLA – Sept. 10

Newton-John is a member of the Moffitt Cancer Center & Research Institute Board of Advisors. Also posted to WKRN, Caribbean Broadcasting Corporation

 

Challenges Remain in MPN Diagnosis and Drug Development

OncLive – Sept. 10

“Trying to get additional agents on board especially for different phenotypes of [myelofibrosis] is where I see the field going,” said Kuykendall, an assistant member of Moffitt Cancer Center.

 

Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies

BioSpace – Sept. 10

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that it has entered into a strategic collaboration with Moffitt Cancer Center to develop multi‑targeted chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with AML and B‑cell malignancies. 

 

Updated Data Confirm Survival, QoL Benefit With Lutathera in GI NETs

OncLive – Sept. 9

The NETTER-1 study, led by Jonathan R. Strosberg, MD, compared Lutathera with high-dose octreotide for patients with grade 1 or 2 metastatic midgut NETs. 

 

Tampa Bay bankers, CFO selected to national list of influential finance executives

Tampa Bay Business Journal – Sept. 7

The Bank of Tampa's Bill West, Pilot Bank's Rita Lowman and Moffitt Cancer Center's Yvette Tremonti have been selected to a national list of notable financial executives.

 

Local cancer survivor shares story ahead of "Stand Up To Cancer" broadcast

WESH – Sept. 7

This morning on Sunrise, we sat down with Jan Freeland, a local cancer survivor, who was helped by the "stand Up To Cancer" research programs. The annual "Stand Up To Cancer" special airs tonight at 8 p.m. on WESH 2.

 

Dr. Chavez on Blinatumomab in ALL

OncLive – Sept. 7

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

 

Dr. Komrokji on the Changing Landscape of AML

OncLive – Sept. 7

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).

 

Baz Highlights Emerging Regimens in Relapsed/Refractory Myeloma

OncLive- Sept. 7

In an interview during the 2018 OncLive® State of the Science Summit™ on Hematologic Malignancies, Baz, associate member, head of the Myeloma Section at Moffitt Cancer Center, discussed these studies and highlighted others that are demonstrating equally impressive response rates in patients with relapsed/refractory multiple myeloma.

 

One-Size-Fits-All Approach Not Applicable in MCL

OncLive – Sept. 7

The current state of treatment for patients with mantle cell lymphoma (MCL), continues to be challenging, according to Bijal D. Shah, MD.

 

Finding the Right Therapy for High-Risk Mantle Cell Lymphoma

CURE - Sept. 7

Patients with high-risk mantle cell lymphoma may also have more proliferative disease and carry P53 mutations, and in turn, could experience worse outcomes when treated with common therapies, explained Bijal D. Shah, M.D., oncologist at the Moffitt Cancer Center.

 

6 months since first reports on glioblastoma concerns in St. Lucie County

WPTV – Sept. 7

They continue to travel to Moffitt for cancer treatments in Tampa. Also  posted to WFLX.

 

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.